StockNow
CalendarLog in
Global Markets

Novo Nordisk (NOVOB DC) announces topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, with CagriSema proving superior to tirzepatide and weight loss of 21%

StockNow breaking-news AI analysis

Novo Nordisk announced phase 3 REIMAGINE 5 and REDEFINE 9 topline results, showing once-weekly CagriSema achieved 21% weight loss and demonstrated superiority over tirzepatide.

2 stocks
NVONovo-Nordisk A/S$41.24Current priceLLYEli Lilly & Co.$1,143.74Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

UKMTO has received a report of an incident involving a vessel transiting the Strait of Hormuz, reported at 07:30 UTC; tanker conducting an inbound transit was struck by an unknown projectile

Geopolitics

Source in Pakistan’s Interior Ministry says Minister Naqvi is heading to Tehran to discuss mediation efforts and ending the stalemate, Al Jazeera reports

Geopolitics

Yemeni Houthi official warns Egypt, Turkey and Pakistan will likely be targeted in the next stages